RA Capital Management reports purchase of Artiva Biotherapeutics common shares worth $194,237.66
ARTV•RA Capital Management increases Artiva Biotherapeutics stake
RA Capital Management, a director and 10% owner of Artiva Biotherapeutics, increased its stake through open-market common stock purchases.
Holding rose to 16,817,573 shares, reflecting net buying of 21,654 shares at weighted-average prices of $8.97 and $8.94.
